7 Stories Sending Dow Healthcare Stocks for a Ride This Week

Johnson & Johnson (NYSE:JNJ): Current price $81.52

Mallinckrodt, the pharmaceuticals division of Covidien, reported that it introduced the 36 and 54 milligram dosage strengths of Methylphenidate HCl Extended-Release Tablets USP, generic version of Concerta. The two dosage strengths will be available, in addition to the 27 mg dosage strength. The 27 mg dosage strength was launched in December 2012, when Mallinckrodt won approval from the FDA to manufacture and market the tablets in 27, 36, and 54 mg dosage strengths.

More than one Supreme Court justice appeared to be skeptical concerning the practice of brand name pharmaceutical firms paying generic companies to keep their less expensive drugs off the market for a longer time, according to The New York Times, which also said that some of the justices seemed to be interested in issuing a narrow ruling that would not form a precedent.

The stock market is at 5-year highs! Discover the best stocks to buy in today’s market. CLICK HERE for Your Stock Investor Cheat Sheet NOW!

JNJ

Don’t Miss: Which President is the King of the Fiscal Squeeze?

Pfizer (NYSE:PFE): Current price $28.86

The Japanese Ministry of Health, Labor and Welfare has approved Pfizer’s Xeljanz for the treatment of adults suffering from rheumatoid arthritis who have had an inadequate response to existing therapies. The drug may be used in patients in whom clinical symptoms due to the disease remain even after appropriate treatment with at least one other disease-modifying antirheumatic drug, such as methotrexate. Xeljanz will be available in Japan after the National Health Insurance listing and will be co-promoted there by Pfizer and Takeda Pharmaceutical Company Limited. Pfizer and Takeda also currently co-promote the RA drug Enbrel in that country.

More than one Supreme Court justice appeared to be skeptical concerning the practice of brand name pharmaceutical firms paying generic companies to keep their less expensive drugs off the market for a longer time, according to The New York Times, which also said that some of the justices seemed to be interested in issuing a narrow ruling that would not form a precedent.

KineMed reported the renewal of a non-exclusive research partnership with Pfizer to move forward novel approaches towards metabolic disease, and in particular Type II Diabetes. The collaboration will utilize KineMed’s unique dynamic proteomics tech platform to map out the impact of potential drug candidates upon specific metabolic pathways.

Pfizer reported that the European Commission has awarded conditional marketing authorization for Bosulif in the European Union for the treatment of adult patients suffering from chronic phase, accelerated phase and blast phase Philadelphia chromosome positive chronic myelogenous leukemia previously treated with at least one tyrosine kinase inhibitors, and for whom imatinib, nilotinib, and dasatinib are not indicated as appropriate treatment options.

The stock market is at 5-year highs! Discover the best stocks to buy in today’s market. CLICK HERE for Your Stock Investor Cheat Sheet NOW!

PFE

Merck & Co. (NYSE:MRK): Current price $44.27

Merck reports that the Biologics License Application for its investigational Timothy grass pollen allergy immunotherapy tablet, has been accepted for review by the FDA. In March, the firm also submitted a BLA to the FDA for its investigational ragweed pollen tablet. The application for Merck’s grass pollen tablet is supported by Phase III trials that studied the safety and efficacy of the investigational product, including a long-term, multi-season trial.

NEW! Discover a new stock idea each week for less than the cost of 1 trade. CLICK HERE for your Weekly Stock Cheat Sheets NOW!

MRK

Don’t Miss: Intel Has Plans That Could Revolutionize Pay-TV.

More from The Cheat Sheet